2014, Clinical Trials, DEA and Packaging

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2014

Clinical Trials

DEA

Packaging

Cannabis Industry Leaders Speak With CLR on Current Delta 8 Issues In The Industry

Cannabis Law Report

JUNE 4, 2021

We believe there is a benefit to Delta-8 but there should be labeling or warnings on packages so that consumers are informed of potential minor intoxication effects. As a graduate student, he received the IPMI Richard Rubin Memorial Scholarship in 2014 for his research in precious metals.

Research and Development

Research and Development Seed-To-Sale Cannabinoids THC

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 32: United States DEA.

Extraction

Extraction Pharmaceutical CBD Epilepsy

Medical Cannabis Brief

Cannabis Industry Leaders Speak With CLR on Current Delta 8 Issues In The Industry

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Stay Connected